SCHEMBL6477648

SCHEMBL6477648

Cc1c(=O)c(Cc2ccc(F)c(F)c2)cn2nc(C(=O)NCc3ccccc3)oc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.42
TP53 P04637 1/20 0.42
PTGER4 P35408 1/20 0.41
THRB P10828 1/20 0.39
P2RX7 Q99572 1/20 0.39
S1PR3 Q99500 2/20 0.38
MAPT P10636 1/20 0.38
CACNA1G O43497 3/20 0.37
CACNA1H O95180 3/20 0.37
CACNA1I Q9P0X4 3/20 0.37
KDM4E B2RXH2 2/20 0.37
CYP2C19 P33261 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6818812 0.91 CHRM4 (0.37) POLBTP53PTGER4THRBP2RX7
SCHEMBL6484109 0.86 PTGER4 (0.42) TP53PTGER4KDM4EALDH1A1HPGD
SCHEMBL6478088 0.80 PTGER4 (0.41) POLBPTGER4P2RX7S1PR3MAPT
SCHEMBL6477100 0.80 CHRM4 (0.43) PTGER4P2RX7S1PR3MAPTCACNA1G
SCHEMBL6292842 0.76 PTGER4 (0.42) POLBTP53PTGER4THRBS1PR3
SCHEMBL6476858 0.75 TRPA1 (0.49) PTGER4S1PR3MAPTCACNA1GCACNA1H
SCHEMBL6813648 0.73 NAMPT (0.39) CACNA1GCACNA1HCACNA1IALDH1A1MAPK1
SCHEMBL6818605 0.72 ALDH1A1 (0.42) S1PR3KDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL6475923 0.72 MAPT (0.46) POLBTP53THRBMAPTKDM4E
SCHEMBL6289333 0.72 LMNA (0.44) TP53THRBMAPTKDM4ECYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 POLB 2396/4885TP53 608/4885PTGER4 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.